Program
Denosumab
Also written as “denosumab”, “CT-P41” and “AMG 162”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Breast Neoplasms · Giant Cell Tumor of Bone · Prostatic Neoplasms, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 553 open or running | phase 4since Nov 20, 2012 | Aug 6, 2002 | Jan 23, 2027phase 4 · NCT06332014 |
| GlaxoSmithKline | 50 open or running | phase 3since Oct 20, 2011 | Oct 20, 2011 | none ahead |
| Celltrion | 30 open or running | phase 3since Feb 12, 2021 | Aug 11, 2020 | none ahead |
| Mabwell (Shanghai) Bioscience | 30 open or running | phase 3since Jan 18, 2022 | Mar 12, 2021 | none ahead |
| Daiichi Sankyo | 20 open or running | phase 3since May 16, 2008 | May 16, 2008 | none ahead |
| Fosun Pharma | 20 open or running | phase 3since Apr 23, 2022 | Aug 27, 2020 | none ahead |
| Shanghai Biomabs Pharmaceutical | 20 open or running | phase 3since Oct 15, 2020 | Apr 18, 2019 | none ahead |
| aryogen-pharmed-co | 10 open or running | phase 3since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Hamad Medical | 10 open or running | phase 3since Jan 22, 2017 | Jan 22, 2017 | none ahead |
| lambda-therapeutic-research-ltd | 11 open or running | phase 3since Jun 7, 2022 | Jun 7, 2022 | none ahead |
| Luye Pharma Group | 11 open or running | phase 3since May 2, 2023 | May 2, 2023 | none ahead |
| Samsung Bioepis | 10 open or running | phase 1since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Taizhou Mabtech Pharmaceutical | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 9, 2007.
- Oct 7, 2020Phase 4 study in Giant Cell Tumor of BoneAmgen · NCT04586660 · 36 enrolled · China, Taiwan
- Oct 15, 2020Phase 3 study in Osteoporosis, PostmenopausalShanghai Biomabs Pharmaceutical · NCT04591275 · 278 enrolled · China
- Nov 3, 2020Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT04621318 · 168 enrolled · United States, France
- Feb 12, 2021Phase 3 study in Postmenopausal Women With OsteoporosisCelltrion · NCT04757376 · 479 enrolled · Estonia, Latvia, Poland and more
- Mar 12, 2021Mabwell (Shanghai) Bioscience's first study: phase 1 study in Osteoporosis, PostmenopausalNew to Mabwell (Shanghai) BioscienceMabwell (Shanghai) Bioscience · NCT04798313 · 120 enrolled · China
- Jan 18, 2022Phase 3 study in Osteoporosis, PostmenopausalMabwell (Shanghai) Bioscience · NCT05215977 · 448 enrolled · China
- Apr 23, 2022Phase 3 study in PostmenopausalFosun Pharma · NCT05352516 · 514 enrolled · China
- Jun 7, 2022lambda-therapeutic-research-ltd's first study: phase 3 study in Osteoporosis, PostmenopausalNew to lambda-therapeutic-research-ltdlambda-therapeutic-research-ltd · NCT05419427 · 552 planned · India
- May 2, 2023Luye Pharma Group's first study: phase 3 study in Osteoporosis, PostmenopausalNew to Luye Pharma GroupLuye Pharma Group · NCT05853354 · 392 enrolled · United States, Bulgaria, Czechia and more
- Sep 7, 2023Phase 1 study in Healthy SubjectCelltrion · NCT06037395 · 154 enrolled · Korea, Republic of
- Mar 19, 2024Phase 4 study in OsteoporosisAmgen · NCT06332014 · 102 enrolled · China
- Apr 7, 2024Taizhou Mabtech Pharmaceutical's first study: phase 1 study in Healthy VolunteersNew to Taizhou Mabtech PharmaceuticalTaizhou Mabtech Pharmaceutical · NCT06361355 · 128 enrolled · China
- Sep 5, 2024Phase 4 study in Glucocorticoid-induced OsteoporosisAmgen · NCT06588153 · 102 enrolled · China
- Dec 9, 2024Phase 3 study in Postmenopausal Women OsteoporosisMabwell (Shanghai) Bioscience · NCT06804590 · 280 enrolled · China
Ahead
- Jan 23, 2027Primary completion: phase 4 study in OsteoporosisAmgen · NCT06332014
- Apr 27, 2027Primary completion: phase 4 study in Glucocorticoid-induced OsteoporosisAmgen · NCT06588153
- Mar 7, 2028Primary completion: phase 4 study in Giant Cell Tumor of BoneAmgen · NCT04586660
TargetBeta
“A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity”NCIt, by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF11
Studies
The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06804590Postmenopausal Women Osteoporosis · China | 3 | Completed | Mabwell (Shanghai) Bioscience | Apr 24, 2026 | 280 |
| NCT06588153Glucocorticoid-induced Osteoporosis · China | 4 | Active, not recruiting | Amgen | Apr 27, 2027 | 102 |
| NCT06361355Healthy Volunteers · China | 1 | Completed | Taizhou Mabtech Pharmaceutical | Jun 3, 2024 | 128 |
| NCT06332014Osteoporosis · China | 4 | Active, not recruiting | Amgen | Jan 23, 2027 | 102 |
| NCT06037395Healthy Subject · Korea, Republic of | 1 | Completed | Celltrion | Oct 20, 2022 | 154 |
| NCT05853354Osteoporosis, Postmenopausal · United States, Bulgaria, Czechia and more | 3 | Active, not recruiting | Luye Pharma Group | Jul 30, 2025 | 392 |
| NCT05419427Osteoporosis, Postmenopausal · India | 3 | Recruiting | lambda-therapeutic-research-ltd | Sep 11, 2024 | 552 |
| NCT05352516Postmenopausal · China | 3 | Completed | Fosun Pharma | Dec 17, 2023 | 514 |
| NCT05215977Osteoporosis, Postmenopausal · China | 3 | Completed | Mabwell (Shanghai) Bioscience | Sep 27, 2021 | 448 |
| NCT04798313Osteoporosis, Postmenopausal · China | 1 | Completed | Mabwell (Shanghai) Bioscience | Dec 7, 2020 | 120 |
| NCT04757376Postmenopausal Women With Osteoporosis · Estonia, Latvia, Poland and more | 3 | Completed | Celltrion | May 18, 2023 | 479 |
| NCT04621318Healthy · United States, France | 1 | Completed | Samsung Bioepis | Nov 9, 2022 | 168 |
| NCT04591275Osteoporosis, Postmenopausal · China | 3 | Completed | Shanghai Biomabs Pharmaceutical | Nov 1, 2024 | 278 |
| NCT04586660Giant Cell Tumor of Bone · China, Taiwan | 4 | Active, not recruiting | Amgen | Mar 7, 2028 | 36 |
| NCT04534582Healthy Male Volunteers · China | 1 | Completed | Fosun Pharma | Sep 12, 2023 | 252 |
| NCT04512872Healthy Male Subjects · Australia | 1 | Completed | Celltrion | May 4, 2021 | 30 |
| NCT03925051Osteoporosis, Postmenopausal · China | 1 | Completed | Shanghai Biomabs Pharmaceutical | Mar 21, 2020 | 132 |
| NCT03822078Osteoporosis | 1 | Completed | Amgen | Dec 24, 2004 | 45 |
| NCT03638128Osteogenesis Imperfecta · United States, Australia, Belgium and more | 3 | Terminated | Amgen | Mar 28, 2022 | 75 |
| NCT03301857Giant Cell Tumor of Bone · United States, Australia, France and more | 4 | Completed | Amgen | Jul 27, 2023 | 85 |
| NCT03293108Osteoporosis · Iran, Islamic Republic of | 3 | UNKNOWN | aryogen-pharmed-co | Sep 30, 2020 | 190 |
| NCT03164928Osteoporosis · United States, Australia, Belgium and more | 3 | Completed | Amgen | Dec 13, 2021 | 24 |
| NCT03040765beta-Thalassemia · Qatar | 3 | Terminated | Hamad Medical | Apr 8, 2019 | 17 |
| NCT02352753Osteogenesis Imperfecta · United States, Australia, Belgium and more | 3 | Terminated | Amgen | Mar 26, 2022 | 153 |
| NCT02157948Osteoporosis, Postmenopausal · United States, Canada, Denmark and more | 3 | Completed | Amgen | Jul 2015 | 394 |
| NCT02135640Osteoporosis · China | 1 | Completed | GlaxoSmithKline | Feb 17, 2015 | 64 |
| NCT02101164Bone Diseases | 4 | Withdrawn | Amgen | Nov 2014 | 0 |
| NCT02099461Healthy Volunteer, Female, Breast · United States | 1 | Completed | Amgen | Jul 2014 | 82 |
| NCT02053753Healthy Volunteer · United States | 1 | Completed | Amgen | Aug 2014 | 146 |
| NCT02014467Osteoporosis, Postmenopausal · China | 3 | Completed | GlaxoSmithKline | Aug 2015 | 486 |
| NCT01973569Arthritis, Rheumatoid · Japan | – | Completed | Daiichi Sankyo | Dec 2015 | 679 |
| NCT01951586Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Completed | Amgen | Jul 29, 2016 | 226 |
| NCT01920568Fractures, Bone · China, Singapore, Taiwan | 3 | Completed | GlaxoSmithKline | Feb 2015 | 487 |
| NCT01869686Healthy Volunteer · United States | 1 | Completed | Amgen | Sep 2013 | 12 |
| NCT01824342Castrate-resistant Prostate Cancer · Czech Republic, United Kingdom | 3 | Completed | Amgen | Feb 2014 | 18 |
| NCT01732770Osteoporosis, Postmenopausal · United States, Australia, Belgium and more | 4 | Completed | Amgen | Jan 7, 2015 | 643 |
| NCT01575873Steroid-induced Osteopor, Glucocorticoid-induced Ostepor · United States, Argentina, Belgium and more | 3 | Completed | Amgen | Jun 21, 2016 | 795 |
| NCT01495000Osteoporosis, Postmenopausal · India | 3 | Completed | GlaxoSmithKline | Feb 2013 | 250 |
| NCT01457950Osteoporosis, Postmenopausal · Korea, Republic of | 3 | Completed | GlaxoSmithKline | Dec 2012 | 135 |
| NCT01464931Renal Insufficiency · United States | 1 | Completed | Amgen | Jan 2013 | 32 |
| NCT01419717Neoplasms · Argentina, Austria, Belgium and more | 3 | Completed | Amgen | Aug 10, 2018 | 129 |
| NCT01345019Neoplasms · United States, Australia, Austria and more | 3 | Completed | Amgen | Jul 19, 2016 | 1,718 |
| NCT01294397Bone Diseases, Metabolic · United States | 1 | Terminated | Amgen | Jan 2016 | 19 |
| NCT01221727Osteoporosis, Postmenopausal | 1 | Completed | Amgen | Jul 2011 | 30 |
| NCT01077154Breast Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Amgen | Aug 31, 2017 | 4,509 |
| NCT00980174Bone Diseases, Metabolic | 3 | Completed | Amgen | Jun 21, 2011 | 242 |
| NCT00950911Multiple Myeloma · Czech Republic, United Kingdom | 3 | Completed | Amgen | Feb 2012 | 35 |
| NCT00936897Osteoporosis, Postmenopausal | 3 | Completed | Amgen | Nov 2011 | 833 |
| NCT00925600Neoplasms · United States, Australia, Bulgaria and more | 3 | Completed | Amgen | May 12, 2016 | 769 |
| NCT00919711Osteoporosis | 3 | Completed | Amgen | Dec 21, 2011 | 870 |
| NCT00896532Bone Diseases, Metabolic | 2 | Completed | Amgen | Feb 21, 2011 | 419 |
| NCT00896454Breast Neoplasms · United States, Canada, France and more | 2 | Completed | Amgen | Sep 13, 2012 | 33 |
| NCT00890981Bone Diseases, Metabolic | 3 | Completed | Amgen | Jun 2010 | 79 |
| NCT00838201Neoplasms · United States, Canada, Finland and more | 3 | Completed | Amgen | May 3, 2012 | 384 |
| NCT00680953Osteoporosis · Japan | 3 | Completed | Daiichi Sankyo | Jun 2012 | 1,262 |
| NCT00680992Neoplasms · United States, Australia, Austria and more | 2 | Completed | Amgen | May 17, 2018 | 535 |
| NCT00556374Breast Neoplasms · Austria, Sweden | 3 | Completed | Amgen | Oct 7, 2014 | 3,420 |
| NCT00523341Bone Diseases, Metabolic | 3 | Completed | Amgen | Jul 19, 2015 | 4,550 |
| NCT00518531Osteoporosis | 3 | Completed | Amgen | Jun 1, 2009 | 250 |
| NCT00515463Bone Diseases, Metabolic | 3 | Completed | Amgen | Mar 2008 | 311 |
How it is read
Names in the registry
- “Denosumab”, 41 entries
- “denosumab”, 10 entries
- “CT-P41”, 3 entries
- “AMG 162”, 3 entries
- “Prolia®”, 2 entries
Codes read as this program: CMAB807.
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 21 studies
- Osteoporosis, 16 studies
- Breast Neoplasms, 5 studies
- Giant Cell Tumor of Bone, 4 studies
- Prostatic Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.